UBLISHED papers on radiosurgery of AVMs demonstrate that between 23 and 44% of patients have AVMs located in the basal ganglia, thalamus, or brainstem. 2, 11, 17, 20, 22, 38, 40 By comparison, only 4 to 11% of patients in recent surgical series of AVMs have harbored these lesions in deep locations. 5, 14, 15, 27, 28, 35, 36 Embolization of AVMs is rarely curative and is typically performed as a preoperative adjunctive therapy before resection or radiosurgery. 26 Consequently, radiosurgery is generally accepted as the best treatment for patients with deeply located AVMs. Nevertheless, there have been few studies in which a specific analysis of the results of radiosurgery for such patients has been undertaken. 4, 23 In this paper, the outcomes of 56 patients who underwent stereotactic radiosurgery for AVMs located in the basal ganglia, thalamus, or brainstem are presented.
Object. Although stereotactic radiosurgery is frequently performed for arteriovenous malformations (AVMs) in deep locations, outcomes after radiosurgery for these patients have not been well studied. The goal of this paper was to study these outcomes.
Methods. Between 1990 and 2000, 56 patients underwent radiosurgery for AVMs located in the basal ganglia (10 patients), thalamus (30 patients), or brainstem (16 patients). The median age of these patients was 34.2 years. Thirty-five patients (62%) had experienced previous bleeding. The AVMs were classified Grade IIIB in 62% of patients and Grade IV in 38% according to the modified Spetzler-Martin Scale; the median radiosurgery-based AVM score was 1.83. The median volume of the lesion was 3.8 cm 3 and the median radiation dose delivered to its margin was 18 Gy. The median duration of follow-up review after radiosurgery was 45 months (range 3-121 months).
In seven patients (12%) hemorrhage occurred at a median of 12 months after radiosurgery; five patients (9%) died and two recovered without any deficit. Permanent radiation-related complications occurred in six (12%) of 51 patients (excluding the five patients who died of hemorrhage) after one procedure and in three (18%) of 17 patients after repeated radiosurgery. Obliteration of the AVM was noted in 24 patients (43%; obliteration was confirmed by angiography in 18 patients and by magnetic resonance [MR] imaging in six patients) after a single procedure and in 32 patients (57%; confirmed by angiography in 25 patients and by MR imaging in seven patients) after one or more procedures. Excellent outcomes (obliteration of the lesion without any new deficit) were obtained in 39% of patients after one radiosurgical procedure and in 48% after one or more procedures. Twelve (67%) of 18 patients with AVM scores lower than 1.5 had excellent outcomes compared with 15 (39%) of 38 patients with AVM scores greater than 1.5 (p = 0.053).
Conclusions. Less than half of the patients with deeply located AVMs were cured of the future risk of hemorrhage without new neurological deficits. This experience emphasizes the difficulty in treating patients with deeply located AVMs; the majority of whom are also poor candidates for resection or embolization.
Follow-up review of cases consisted of clinical examination and MR imaging studies performed 1, 2, and 3 years after radiosurgery. Follow-up angiography was available for 46 patients (82%) 2 or more years after radiosurgery. The status of the AVM in the other 10 patients was based on MR imaging. 31 Patients in whom a residual AVM was identified on follow-up angiograms were reevaluated for repeated radiosurgery based on their ages, clinical conditions, and the response of the AVM to the first radiosurgical procedure. Seventeen patients (30%) underwent repeated radiosurgery at a median of 42 months (range 36-53 months) after the first radiosurgery. The median volume of the AVM at repeated radiosurgery was 3.7 cm 3 (range 0.6-9.8 cm 3 ) and the median volume reduction was 55% (range Ϫ92% to ϩ104%). The median dose delivered to the margin of the AVM was 18 Gy (range 14-20 Gy), and the median maximal radiation dose was 36 Gy (range 32-40 Gy).
Patient outcomes were classified as excellent (complete obliteration and no new deficit), good (complete obliteration, but a minor deficit), fair (complete obliteration, but a major deficit), unchanged (residual AVM and no deficit), poor (persistent AVM and any new deficit), and dead. Five patients died of AVM hemorrhages at a median of 12 months (range 3-14 months) after radiosurgery. The median duration of follow-up review in the remaining 51 patients was 45 months (range 12-121 months). Comparisons of ratio were performed using the Fisher exact test.
Results

Hemorrhage After Radiosurgery
Seven patients (12%) experienced AVM hemorrhages at a median of 12 months (range 3-43 months) after radiosurgery. In four the AVM was located in the thalamus and in three the AVM was in the basal ganglia. No patient in whom the AVM was located in the brainstem experienced a hemorrhage after radiosurgery. Five patients (9%) died. In one patient a hemiparesis developed, but resolved without treatment. One patient had a headache, but remained neurologically unchanged. The actuarial risk of postradiosurgical hemorrhage was 7% for Year 1, 4% for Year 2, 2% for Years 3 and 4, and 0% thereafter.
Adverse Radiation Effects
Eleven patients experienced new deficits that were associated with regions of increased signal on MR images after radiosurgery. Excluding the five patients who died of AVM hemorrhage, the crude risk of radiation-related deficits was 22%. Seven patients (14%) experienced deficits after they underwent one radiosurgical procedure; these deficits included hemiparesis in five patients and leg weakness and temporary hand numbness in one patient each. The incidence of new permanent deficits was 12%. Radiation-related deficits occurred in four (24%) of 17 patients who underwent repeated radiosurgery. The deficits included temporary hemiparesis, diplopia, hemiparesis, and leg weakness, which occurred in one patient each. The incidence of new permanent deficits after repeated radiosurgery was 18%. Seven (20%) of 35 patients with AVMs of the basal ganglia or thalamus experienced permanent radiationrelated deficits, compared with two (12%) of 16 patients with AVMs of the brainstem (p = 0.7). The actuarial risk of radiation-related complications at 1, 2, and 5 years after one or more radiosurgical procedures was 5, 12, and 27%, respectively.
Status of the AVM
Nidus obliteration was confirmed by angiography after one radiosurgical procedure in 18 patients. If we assume that AVM obliteration did not occur in any other patient, the obliteration rate was 32%. In six patients there was evidence of obliteration on MR images. When we add these patients to the 18 patients, this brings the AVM cure rate to 43%. Nidus obliteration after one or more radiosurgical procedures was confirmed by angiography in 25 patients. Again, if we assume that the lesion was not obliterated in any other patient, the obliteration rate was 45%. If the seven other patients in whom MR imaging confirmed obliteration are included the overall AVM cure rate was 57%. No difference was noted in obliteration rates between AVMs located in the basal ganglia or thalamus and those located at the brainstem after one radiosurgical procedure (16 16 patients, respectively; p = 0.77). The actuarial rate of an AVM cure (including those confirmed by both angiography and MR imaging) after one or more radiosurgical procedures was 20, 47, and 66% at 2, 3, and 4 years after radiosurgery, respectively.
Patient Outcomes
Patient outcomes after radiosurgery are detailed in Table  2 . As outlined previously, 14 patients (25%) suffered a new deficit (nine patients) or died (five patients) of either AVM hemorrhage or a permanent radiation-related injury; no patient experienced both a hemorrhage and a radiation-related complication. Excellent outcomes were achieved in 22 patients (39%) after a single radiosurgical procedure and in 27 patients (48%) after one or more radiosurgical procedures. Location of the AVM (basal ganglia or thalamus compared with brainstem) did not correlate with excellent outcomes (18 who had radiosurgery-based AVM scores lower than 1.5 had excellent outcomes compared with 15 (39%) of 38 patients with AVM scores greater than 1.5 (p = 0.053) (Fig. 2) .
Discussion
Natural History of Deeply Located AVMs
The successful management of deeply located AVMs is one of the most formidable challenges facing neurosurgeons. In general, AVMs are associated with a 2 to 4% annual hemorrhage risk. 1, 3, 13, 16, 25 A deep location for these lesions, however, has been identified as a risk factor for bleeding, and the chance that a neurological deficit may accompany each hemorrhage is greater for patients with AVMs in the basal ganglia, thalamus, or brainstem. Recently, Fleetwood and associates 7 examined the natural history of AVMs in the basal ganglia or thalamus that were managed at Stanford University between 1986 and 2001. During that 15-year period, 96 patients harboring these lesions were evaluated. Seventy-two percent of the patients presented with an intracranial hemorrhage and 86% of patients with a hemorrhage demonstrated either hemiparesis or hemiplegia. With more than 500 total patient-years of conservative management, the annual risk of hemorrhage was 9.8%. Other studies on deeply located AVMs have produced similar findings. According to Lawton and colleagues 18 and Sasaki, et al., 34 88 and 91% of patients presented with intracranial hemorrhage, respectively. Sasaki, et al., found that 10 of 14 patients who were treated conservatively experienced bleeding during 88 patient-years of follow up, giving an annual hemorrhage rate of 11.4%. Of course, this information has been derived from retrospective studies at academic centers and, therefore, may not truly represent the natural history of this malformation.
Nonetheless, these studies demonstrate the significant risk associated with conservative management of AVMs in deep locations.
Resection and Endovascular Therapy
Making the situation worse is the fact that the treatment options available to patients with AVMs in deep locations are quite limited. Unlike angiographically occult vascular malformations, which can be resected safely by using modern microsurgical techniques, 33, 37 few neurosurgeons commonly recommend resection of deeply located AVMs. Liu and Lee 21 reported 16 cases in which excision of AVMs in the basal ganglia or thalamus was performed before radiosurgery became locally available in 1993. Complete AVM removal was performed in every case, and 11 patients (69%) either improved or remained neurologically stable. Two patients (12%) suffered postoperative hemiparesis. Conversely, Lawton and colleagues 18 found that six (43%) of 14 patients with AVMs of the thalamus, basal ganglia, or brainstem were cured of the future risk of bleeding by using embolization, surgery, or combined treatment for these lesions. Morgan, et al., 24 analyzed the results of surgery for 92 patients with AVMs supplied by the middle cerebral artery, with an emphasis on the risks associated with the lenticulostriate arterial supply. Five (83%) of six patients who harbored a Spetzler-Martin Grade III AVM that was fed by lenticulostriate arteries and, thereby, located in the basal ganglia or internal capsule, suffered a new neurological deficit. Paulsen, et al., 26 described the results of embolization in patients with AVMs of the basal ganglia or thalamus. Overall, 38 patients underwent 69 embolization sessions before radiosurgery (19 patients), microsurgery (five patients), or both radiosurgery and microsurgery (13 patients). Only one patient was treated with endovascular techniques alone. Four patients (11%) experienced permanent neurological deficits that were related to the embolization. The authors concluded that embolization can obliterate a significant portion of these AVMs and may permit complete obliteration when combined with resection or radiosurgery as part of a multimodal treatment regimen.
Radiosurgery of AVMs in Deep Locations
As an alternative to resection or endovascular therapy, radiosurgery has become the primary treatment option for the majority of patients with deeply located AVMs. Massager, et al., 23 reviewed the radiosurgical experiences at the University of Pittsburgh and Marseille gamma knife centers for patients with AVMs located at the brainstem. Eighty-seven patients underwent radiosurgery between 1987 and 1999, and the majority (74%) of these patients had suffered a prior hemorrhage. The average AVM volume was 1.3 cm 3 , and the median dose delivered to the margin of the lesion was 21.3 Gy. Twenty-nine (63%) of 46 patients who were available for follow-up imaging 2 or more years postradiosurgery attained AVM obliteration, as confirmed by angiography (21 patients) or MR imaging (eight patients). Three patients experienced bleeding after radiosurgery. One of these patients died and the other two recovered without any deficit. Five (8%) of 65 patients experienced clinical deterioration that was related to T 2 -weighted signal changes on MR images. Crocco 4 reported the results of radiosurgery in 33 patients with AVMs located in the basal ganglia region (corpus striatum, internal capsule, or thalamus). Thirty-one patients (94%) presented after a hemorrhage. An average radiation dose of 21.6 Gy was delivered to the margin of the lesion to cover a mean AVM volume of 3 cm 3 . Twenty-six patients participated in at least 6 months of follow-up review and 21 patients in more than 2 years. One patient (4%) experienced adverse effects of radiation. In two patients (8%) hemorrhage occurred after radiosurgery, resulting in a new permanent deficit in one patient and death of the other patient. Follow-up angiography confirmed complete obliteration in 17 (81%) of 21 patients at a mean of 24 months after radiosurgery. Crocco concluded that radiosurgical outcomes are similar between patients with AVMs in the basal ganglia region and patients with cortical AVMs and that radiosurgery should be considered the first treatment for patients with AVMs of the basal ganglia region that are smaller than 10 cm 3 in volume. Our study provides additional information regarding the results of radiosurgery for patients with deeply located AVMs. First, although the annual rate of postradiosurgical bleeding does not appear to be any different for this group, the neurological risk associated with each hemorrhage appears to be much higher. In this series, five of seven patients died after they experienced hemorrhage from their AVMs. Second, the risk of radiation-related complications was greater for patients with deeply located AVMs than for those with superficially located AVMs. For example, the actuarial risk of developing radiation-related complications after one or more radiosurgical procedures in this study was 5, 12, and 27% at 1, 2, and 5 years, respectively. This compares with only 3 to 5% of patients experiencing symptomatic radiation effects after radiosurgery for cortical AVMs. 9, 19 Third, the obliteration rate we observed was lower than that cited in previous reports on radiosurgery of AVMs. 10 Complete obliteration was attained in 43% of our patients after one procedure and only 57% were cured after one or more radiosurgical procedures. It is noteworthy that 82% of our patients underwent follow-up angiography as opposed to 37 to 64% of patients in other studies of radiosurgery of deeply located AVMs. Two factors, dose reduction and exclusion of the nidus from the treated volume, are likely to be the cause of the reduced obliteration rate after radiosurgery of deeply located AVMs. For example, clinical observations and the integrated logistic formula would predict that more than 20 Gy should be a safe margin dose for the AVMs in our series (median volume 3.6 cm 3 ), 8, 9, 19, 39 yet the median dose prescribed was 18 Gy. In an attempt to reduce the volume treated, and thus minimize risk of radiation-related complications, it is probable that in the present study the entire nidus was not covered at the time of radiosurgery in more patients than in other studies. Such marginal or geographic misses are the most common cause of failed radiosurgery for AVMs. 6, 12, 32 Combining all these factors together, it is not surprising that the number of patients in whom the AVM was cured without new neurological deficits is lower than that typically discussed after radiosurgery.
Less than one half of our patients had an excellent outcome after one or more radiosurgical procedures. Does this mean that radiosurgery is inappropriate for patients with deeply located AVMs? Our results suggest that we can predict those patients who are most likely to be cured of the future risk of hemorrhage with an acceptable level of morbidity. Sixty-seven percent of patients with a radiosurgerybased AVM score of less than 1.5 had excellent outcomes compared with only 39% whose AVM score exceeded 1.5 (p = 0.053). 29 Therefore, younger patients with smaller-volume AVMs in deep locations will have lower radiosurgerybased AVM scores and are thus most likely to benefit from radiosurgery compared with the natural history of untreated deeply located AVMs. In addition, patients with AVM scores between 1.5 and 2.25 had greater than a 50% chance of obliteration without new deficits. Thus, most patients with AVMs in deep locations and radiosurgery-based scores below 2.25 will have better outcomes after radiosurgery than if the lesions are allowed to follow their natural history. 7, 34 In our series, 42 (75%) of 56 patients had AVM scores lower than 2.25. Conversely, only two (14%) of 14 patients with AVM scores higher than 2.25 had an excellent outcome. Consequently, radiosurgery may have little impact on outcomes for older patients or for those with large-volume AVMs at deep locations, and observation may be an acceptable treatment strategy for these patients. It remains to be seen whether staged-volume radiosurgery for AVMs can significantly improve the success rate of radiosurgery for patients who are unlikely to be cured after a single session of radiosurgery. 30 
Conclusions
Radiosurgery of AVMs in deep locations has a relatively high risk of radiation-related complications and a lower rate of obliteration compared with the results of radiosurgery for superficial AVMs. Our findings, although sobering, do not take away from the fact that radiosurgery remains the mainstay of care for patients with deeply located AVMs because neither resection nor endovascular therapy provides a better
